Effect of lymph node metastasis characteristics on local regional recurrence in stage pN1 non-small cell lung cancer

doi:10.3877/cma.j.issn.1674-0785.2022.05.002

Abstract

Abstract:

Objective

To explore therisk factors forlocoregional recurrence in stage pN1non-small cell lung cancer patients, and identify potential candidates for adjuvant radiotherapy.

Methods

Patients diagnosed with stage pN1 non-small cell lung cancer who received radical surgery atBeijing Cancer Hospital between November 2009 and December 2016 were enrolled. The clinical, pathological, and surveillancedata of the patients were collected. The primary endpoint was locoreginal recurrence free survival (LRFS). Lymph node characteristics including extracapsular extension, lymph node ratio, multistation metastasis, distribution of metastaticlymph nodes, etc. were analysed by univariate and multivariate analyses.

Results

A total of 257 patients were enrolled, among whom 159 were male and 98 were female. The median age was (58.5±8.5) years (range: 35~80 years). The median follow-up time was 58months(range: 5~131 months). The 5-year LRFS rate for the entire cohort was 69.7%. Multivariate analysis demonstratedthat extracapsular extension (HR=1.96, 95%CI: 1.09~3.51, P=0.024) and lymph node ratio >0.1 (HR=2.28, 95%CI: 1.03~5.07, P=0.043) were significantly correlated with lower LRFS.

Conclusion

Extracapsular extension and lymph node ratio >0.1 are risk factors for locoregional recurrence in stage pN1non-small cell lung cancer. Patients carrying those risk factors might potentially benefit from adjuvant radiotherapy.

Key words: Carcinoma, non-small-cell lung, Locoreginal recurrence, Extracapsular extension, Lymph node ratio

Jianyi Yang, Xin Yang, Zhiwei Zhou, Zeming Ma, Jia Wang, Yue Yang. Effect of lymph node metastasis characteristics on local regional recurrence in stage pN1 non-small cell lung cancer[J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(05): 385-390.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2022.05.002

https://zhlcyszz.cma-cmc.com.cn/EN/Y2022/V16/I05/385

Figures/Tables 3

References 27

1	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66(2):115-132. DOI: 10.3322/caac.21338.
2	Okami J, Shintani Y, Okumura M, et al. Demographics, safety and quality, and prognostic information in both the seventh and eighth editions of the tnm classification in 18,973 surgical cases of the japanese joint committee of lung cancer registry database in 2010 [J]. J Thorac Oncol, 2019, 14(2):212-222. DOI: 10.1016/j.jtho.2018.10.002.
3	Rusch VW, Asamura H, Watanabe H, et al. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer [J]. J Thorac Oncol, 2009, 4(5):568-577. DOI: 10.1097/JTO.0b013e3181a0d82e.
4	Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer [J]. J Thorac Oncol, 2016, 11(1):39-51. DOI: 10.1016/j.jtho.2015.09.009.
5	Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group [J]. J Clin Oncol, 2008, 26(21):3552-3559. DOI: 10.1200/JCO.2007.13.9030.
6	Dziedzic DA, Rudzinski P, Langfort R, et al. Risk factors for local and distant recurrence after surgical treatment in patients with non-small-cell lung cancer [J]. Clin Lung Cancer, 2016, 17(5):e157-e167. DOI: 10.1016/j.cllc.2015.12.013.
7	Luo H, Qiao L, Liang N, et al. Risk factors for recurrence in patients with resected N1 non-small cell lung cancer - a systematic review and meta-analysis [J]. J BUON, 2015, 20(3):791-799.
8	Robinson CG, Patel AP, Bradley JD, et al. Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base [J]. J Clin Oncol, 2015, 33(8):870-876. DOI: 10.1200/JCO.2014.58.5380.
9	Trodella L, Granone P, Valente S, et al. Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: definitive results of a phase Ⅲ randomized trial [J]. Radiother Oncol, 2002, 62(1):11-19. DOI: 10.1016/s0167-8140(01)00478-9.
10	仲佳. 《CSCO非小细胞肺癌诊疗指南2021》更新要点解读 [J]. 实用肿瘤杂志, 2022, 37(1):8-15. DOI: 10.13267/j.cnki.syzlzz.2022.002.
11	Gradishar WJ, Anderson BO, Abraham J, et al. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology [J]. J Natl Compr Canc Netw, 2020, 18(4):452-478. DOI: 10.6004/jnccn.2020.0016.
12	Asamura H, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer [J]. J Thorac Oncol, 2015, 10(12):1675-1684. DOI: 10.1097/JTO.0000000000000678.
13	Fujimoto T, Cassivi SD, Yang P, et al. Completely resected N1 non-small cell lung cancer: factors affecting recurrence and long-term survival [J]. J Thorac Cardiovasc Surg, 2006, 132(3):499-506. DOI: 10.1016/j.jtcvs.2006.04.019.
14	Varlotto JM, Medford-Davis LN, Recht A, et al. Failure rates and patterns of recurrence in patients with resected N1 non-small-cell lung cancer [J]. 2011, 81(2):353-359.
15	Higgins KA, Chino JP, Berry M, et al. Local failure in resected N1 lung cancer: implications for adjuvant therapy [J]. Int J Radiat Oncol Biol Phys, 2012, 83(2):727-733. DOI: 10.1016/j.ijrobp.2011.07.018.
16	Burdett S, Rydzewska L, Tierney J, et al. Postoperative radiotherapy for non-small cell lung cancer [J]. Cochrane Database Syst Rev, 2016, 10(10):CD002142. DOI: 10.1002/14651858.CD002142.pub4.
17	Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group [J]. Lancet, 1998, 352(9124):257-263.
18	Mikell JL, Gillespie TW, Hall WA, et al. Postoperative radiotherapy is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes: results of an analysis of the National Cancer Data Base [J]. J Thorac Oncol, 2015, 10(3):462-471. DOI: 10.1097/JTO.0000000000000411.
19	Billiet C, Decaluwé H, Peeters S, et al. Modern post-operative radiotherapy for stage Ⅲ non-small cell lung cancer may improve local control and survival: a meta-analysis [J]. Radiother Oncol, 2014, 110(1):3-8. DOI: 10.1016/j.radonc.2013.08.011.
20	Bhattacharya P, Mukherjee R. Lymph node extracapsular extension as a marker of aggressive phenotype: Classification, prognosis and associated molecular biomarkers [J]. Eur J Surg Oncol, 2021, 47(4):721-731. DOI: 10.1016/j.ejso.2020.09.005.
21	Almangush A, Mäkitie AA, Triantafyllou A, et al. Staging and grading of oral squamous cell carcinoma: An update [J]. Oral Oncol, 2020, 107:104799. DOI: 10.1016/j.oraloncology.2020.104799.
22	Liu W, Shao Y, Guan B, et al. Extracapsular extension is a powerful prognostic factor in stage ⅡA-ⅢA non-small cell lung cancer patients with completely resection [J]. Int J Clin Exp Pathol, 2015, 8(9):11268-11277.
23	Borghetti P, Barbera F, Bonù ML, et al. Resected pN1 non-small cell lung cancer: recurrence patterns and nodal risk factors may suggest selection criteria for post-operative radiotherapy [J]. Radiol Med, 2016, 121(9):696-703. DOI: 10.1007/s11547-016-0648-z.
24	冯雯: ⅢA(N2)期非小细胞肺癌完全切除术后辅助性胸部放疗价值的临床研究 [D]. 上海:复旦大学, 2013.
25	Fan C, Gao S, Hui Z, et al. Risk factors for locoregional recurrence in patients with resected N1 non-small cell lung cancer: a retrospective study to identify patterns of failure and implications for adjuvant radiotherapy [J]. Radiat Oncol, 2013, 8:286. DOI: 10.1186/1748-717X-8-286.
26	Ding X, Hui Z, Dai H, et al. A proposal for combination of lymph node ratio and anatomic location of involved lymph nodes for nodal classification in non-small cell lung cancer [J]. J Thorac Oncol, 2016, 11(9):1565-1573. DOI: 10.1016/j.jtho.2016.05.004.
27	阎石, 吴楠. 基于非小细胞肺癌系统性肺内淋巴结清扫的N1分期改良建议[J]. 中华医学杂志, 2021, 101(35):2748-2750. DOI: 10.3760/cma.j.cn112137-20210621-01402.

	变量	例数	局部区域无复发生存率（%）			单因素分析		多因素分析
	变量	例数	1年	3年	5年	χ²值	P值	HR（95%CI）	P值
年龄（岁）						0.112	0.738
＜65		196	88.1	76.5	70.2
≥65		61	88.4	74.6	68.0
性别						0.508	0.476
男		159	88.4	73.8	66.8
女		98	87.8	79.2	74.0
吸烟史						0.118	0.731
无		118	87.3	77.3	72.0
有		139	94.2	89.0	67.5
原发灶位置						6.160	0.013
上叶		137	92.7	80.4	76.6
中/下叶		120	83.0	70.9	61.5			1.30（0.74-2.27）	0.359
术前CEA						4.693	0.030
正常		195	90.1	78.6	73.1
升高		62	82.2	67.8	58.7			1.50（0.85-2.67）	0.163
病理类型						0.721	0.697
腺癌		168	87.4	74.7	69.2
鳞癌		79	89.9	77.9	68.8
其他		10	90.0	90.0	90.0
T分期						1.564	0.458
T1		143	88.8	77.7	73.2
T2		75	86.3	74.8	65.3
≥T3		39	89.4	71.8	64.3
侵犯脏层胸膜						0.160	0.689
否		157	88.4	76.8	70.6
是		100	89.9	74.8	68.1
脉管癌栓						1.471	0.225
否		184	87.3	76.8	72.4
是		73	90.4	74.1	62.5
术式						0.001	0.969
肺叶切除术		244	87.4	76.2	70.0
全肺切除术		17	100	73.7	65.5
新辅助治疗						0.440	0.507
否		204	87.6	76.0	68.7
是		53	90.6	76.0	73.5
辅助治疗						1.306	0.253
否		73	93.1	79.5	75.6
是		184	86.3	74.7	67.5
淋巴结转移度						11.118	0.004
≤0.05		70	95.7	88.2	83.1
0.05~0.1		84	92.8	76.4	70.0			1.60（0.58~4.38）	0.362
＞0.1		103	79.3	67.2	60.0			3.10（1.09~8.80）	0.034
转移淋巴结站数						6.389	0.011
1		159	91.7	80.9	76.0
≥2		98	82.5	68.1	59.1			0.70（0.30~1.64）	0.407
阳性淋巴结分布						14.434	0.001
肺内		174	93.6	79.0	73.0
肺门/叶间		38	89.5	83.8	80.0			0.75（0.30~1.91）	0.548
都有		45	72.9	57.3	45.8			1.91（0.87~4.21）	0.108
淋巴结被膜外侵犯						11.854	0.003
否			93.9	87.4	80.1
是			77.3	63.4	58.7			2.20（1.23~3.92）	0.008
无资料			92.2	72.2	65.7
活检N2淋巴结个数						3.212	0.073
＜8		77	85.7	79.1	63.6
≥8		180	91.0	79.0	72.4			1.31（0.73~2.35）	0.370

	变量	例数	局部区域无复发生存率（%）			单因素分析		多因素分析
	变量	例数	1年	3年	5年	χ²值	P值	HR（95%CI）	P值
年龄（岁）						0.112	0.738
＜65		196	88.1	76.5	70.2
≥65		61	88.4	74.6	68.0
性别						0.508	0.476
男		159	88.4	73.8	66.8
女		98	87.8	79.2	74.0
吸烟史						0.118	0.731
无		118	87.3	77.3	72.0
有		139	94.2	89.0	67.5
原发灶位置						6.160	0.013
上叶		137	92.7	80.4	76.6
中/下叶		120	83.0	70.9	61.5			1.30（0.74-2.27）	0.359
术前CEA						4.693	0.030
正常		195	90.1	78.6	73.1
升高		62	82.2	67.8	58.7			1.50（0.85-2.67）	0.163
病理类型						0.721	0.697
腺癌		168	87.4	74.7	69.2
鳞癌		79	89.9	77.9	68.8
其他		10	90.0	90.0	90.0
T分期						1.564	0.458
T1		143	88.8	77.7	73.2
T2		75	86.3	74.8	65.3
≥T3		39	89.4	71.8	64.3
侵犯脏层胸膜						0.160	0.689
否		157	88.4	76.8	70.6
是		100	89.9	74.8	68.1
脉管癌栓						1.471	0.225
否		184	87.3	76.8	72.4
是		73	90.4	74.1	62.5
术式						0.001	0.969
肺叶切除术		244	87.4	76.2	70.0
全肺切除术		17	100	73.7	65.5
新辅助治疗						0.440	0.507
否		204	87.6	76.0	68.7
是		53	90.6	76.0	73.5
辅助治疗						1.306	0.253
否		73	93.1	79.5	75.6
是		184	86.3	74.7	67.5
淋巴结转移度						11.118	0.004
≤0.05		70	95.7	88.2	83.1
0.05~0.1		84	92.8	76.4	70.0			1.60（0.58~4.38）	0.362
＞0.1		103	79.3	67.2	60.0			3.10（1.09~8.80）	0.034
转移淋巴结站数						6.389	0.011
1		159	91.7	80.9	76.0
≥2		98	82.5	68.1	59.1			0.70（0.30~1.64）	0.407
阳性淋巴结分布						14.434	0.001
肺内		174	93.6	79.0	73.0
肺门/叶间		38	89.5	83.8	80.0			0.75（0.30~1.91）	0.548
都有		45	72.9	57.3	45.8			1.91（0.87~4.21）	0.108
淋巴结被膜外侵犯						11.854	0.003
否			93.9	87.4	80.1
是			77.3	63.4	58.7			2.20（1.23~3.92）	0.008
无资料			92.2	72.2	65.7
活检N2淋巴结个数						3.212	0.073
＜8		77	85.7	79.1	63.6
≥8		180	91.0	79.0	72.4			1.31（0.73~2.35）	0.370

[1]	Jiabing Yao, Linjiao Jia, Pilei Si, Yi Huang, Bin Fang, Haijun Chen, Wentao Li. Study on the correlation between lymphovascular invasion and lymph node ratio in patients withbreast cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2018, 12(01): 28-31.
[2]	Jianhai Wu, Fanghai Han, Jinzhong Chen. Retrospective analysis of the relationship between metastatic lymph node ratio and survival in stage I~III colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2016, 05(02): 138-147.
[3]	Litao Zhang, Xiujuan Li, Xiaolin Zhu, Zhenbo Ma, Deting Ma, Yuanzhong Xie. Prostate imaging reporting and data system (PI-RADS) for assessment of pathologic outcomes and clinical characteristics in patients with prostate cancer confirmed by biopsy [J]. Chinese Journal of Diagnostics(Electronic Edition), 2017, 05(04): 267-271.
[4]	Litao Zhang, Xiujuan Li, Yaoqi Han, Xiaolin Zhu, Yuanzhong Xie. Predictive value of T2 weighted imaging combined with diffusion magnetic resonance imaging for extracapsular extension in patients with prostate cancer [J]. Chinese Journal of Diagnostics(Electronic Edition), 2016, 04(04): 226-230.

Please choose a citation manager

Content to export